The translocation most typically found in mantle cell lymphoma drags a powerful regulatory element into a new area of the human genome.

Findings suggest that because the brain maps are preserved, it may, theoretically, be possible to restore movement to a ...

Merck’s once-monthly oral HIV prevention pill, MK-8527, advances to Phase III and may offer an accessible PrEP option in the future.

The foundation is launching with an initial slate of grants to local scientific centers of excellence in Seattle.

GEMORNA could turn out to be a sea change for biopharma firms pursuing mRNA-based medicines beyond traditional infectious disease vaccines.

Single-cell proteomics with RNA sequencing uncover hidden gene expression dynamics in stem cell differentiation.

Stem cells cryopreserved on the International Space Station for six months have successfully produced healthy mouse offspring ...

How lipid nanoparticles shape dendritic cell responses has been uncovered, offering insight into safer vaccines and potential autoimmune disease therapies.

The open-source pipeline designs proteins with improved success rates for therapeutic targets, including gene editing proteins and allergens.

A new delivery platform allows protein therapeutics to be delivered in higher concentrations and injected with a standard ...

Blueprint for ovarian reserve cell development identifies critical development milestones, risk factors for hormone-related disorders.

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead pipeline asset bretisilocin, a clinical-stage candidate designed to treat moderate-to-severe major depressive disorder (MDD), for up to $1.